Filing summary: quarter ended March 31, 2019
Issuer identification: The supplied filing is BioSig Technologies, Inc.’s Form 10-Q, not a filing for Streamex Corp. Investors should verify the company and filing identity before relying on this summary.
Business context and reporting period
BioSig is a development-stage medical-device company developing the PURE EP System, intended to improve cardiac signal acquisition during electrophysiology procedures. The system received FDA 510(k) clearance in August 2018; the company had not begun commercialization and reported no revenue or customers. The unaudited quarter covers the three months ended March 31, 2019, with comparison to the same 2018 period.
Financial results and liquidity
- Revenue and gross margin: No revenue or cost of goods sold in either quarter; gross margin is not meaningful.
- Operating expenses: $5.88 million, up from $2.64 million. R&D was $1.49 million, up 72.6%; general and administrative expense was $4.38 million, up 147.1%. Management attributed increases chiefly to added staff, performance pay, consulting, and commercialization activity.
- Loss: Net loss was $5.87 million versus $2.64 million. Loss available to common stockholders was $5.88 million versus $2.94 million; basic and diluted loss per share was $0.33 versus $0.25.
- Cash flow: Operating cash use was $3.52 million, compared with $2.39 million. Investing cash use was $73,024. Financing provided $10.08 million, principally $8.62 million from common-stock sales and $1.46 million from warrant exercises. Cash increased to $10.93 million from $4.45 million at year-end.
- Liquidity and obligations: Working capital was $10.08 million. Current liabilities were $1.01 million; total liabilities were approximately $1.24 million, including $385,367 of lease liabilities and $253,449 of preferred dividends payable. The filing reports no convertible debentures outstanding. Lease liabilities are obligations, not conventional borrowings.
- Equity and dilution: Common shares outstanding increased from 16.87 million at year-end to 20.01 million at March 31. The company also issued 560,000 shares for services valued at $2.33 million and reported $2.67 million of equity-based compensation in operating cash-flow adjustments.
Material changes versus the prior period
Net loss and operating cash use increased substantially as operating expenses rose. Financing proceeds were much higher than in Q1 2018, when financing provided $1.88 million; this helped raise quarter-end cash to $10.93 million versus $1.04 million at March 31, 2018. Preferred dividends fell to $10,541 from $305,046, primarily because of prior-period Series D conversions. The company adopted lease accounting on January 1, 2019, recognizing right-of-use assets and lease liabilities; this accounting change did not represent equivalent cash proceeds.
Outlook, risks, and notable items
- Going concern: The filing says substantial doubt exists about the company’s ability to continue as a going concern, reflecting recurring losses, negative operating cash flow, no revenue, and the need for additional financing. Management believed available funds could support R&D and other requirements for at least 10 months, while also estimating approximately $4 million of additional funding would be needed for the next 12 months. The company expects continued operating losses and higher R&D and administrative costs.
- Product and regulatory outlook: Initial clinical cases using PURE EP were conducted in February 2019, with initial results described as showing improved signal detection and fidelity versus existing equipment. Additional evaluations were planned. Management targeted ISO/MDSAP audit submission in Q2 2019, and expected ISO certification and CE marking in Q4 2019 and Japanese approval by year-end; these were forward-looking targets, not reported outcomes.
- Financing and dilution: The March private placement issued 2,155,127 common shares for $8.62 million. In April, the company reported additional warrant-related proceeds and stock issuances. Future financing may dilute existing holders or require securities with senior rights; inability to raise funds could delay or reduce development and commercialization.
- Other risks and controls: Product development, regulatory approval, commercial viability, market demand, and competition remain uncertain. Management reported that previously identified material weaknesses in internal control over financial reporting had not been remediated and concluded disclosure controls were ineffective as of March 31, 2019. No legal proceedings were reported.
Important facts for investors to verify
- Confirm that BioSig Technologies, Inc., rather than Streamex Corp., is the intended issuer and that the filing corresponds to the requested security.
- Review the going-concern disclosure, cash runway assumptions, and the stated need for roughly $4 million of additional funding over the next 12 months.
- Check subsequent financing, warrant exercises, share-count changes, and potential dilution after March 31, 2019.
- Verify progress and actual outcomes for clinical evaluations, commercialization, ISO/MDSAP, CE marking, and Japanese regulatory approval.
- Assess the size and remediation status of internal-control weaknesses and the effects of substantial stock-based compensation on reported expenses and dilution.